- Home
- EDN vs COGT Comparison
EDN vs COGT Comparison
Compare EDN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- COGT
- Stock Information
- Founded
- EDN 1992
- COGT 2014
- Country
- EDN Argentina
- COGT United States
- Employees
- EDN N/A
- COGT N/A
- Industry
- EDN Electric Utilities: Central
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- COGT Health Care
- Exchange
- EDN Nasdaq
- COGT Nasdaq
- Market Cap
- EDN 1.0B
- COGT 900.3M
- IPO Year
- EDN 2007
- COGT 2018
- Fundamental
- Price
- EDN $42.41
- COGT $7.84
- Analyst Decision
- EDN
- COGT Buy
- Analyst Count
- EDN 0
- COGT 6
- Target Price
- EDN N/A
- COGT $14.20
- AVG Volume (30 Days)
- EDN 258.1K
- COGT 1.8M
- Earning Date
- EDN 12-31-2024
- COGT 11-12-2024
- Dividend Yield
- EDN N/A
- COGT N/A
- EPS Growth
- EDN N/A
- COGT N/A
- EPS
- EDN 0.14
- COGT N/A
- Revenue
- EDN $972,768,196.00
- COGT N/A
- Revenue This Year
- EDN $144.81
- COGT N/A
- Revenue Next Year
- EDN $81.78
- COGT N/A
- P/E Ratio
- EDN $17.03
- COGT N/A
- Revenue Growth
- EDN N/A
- COGT N/A
- 52 Week Low
- EDN $13.78
- COGT $4.28
- 52 Week High
- EDN $51.69
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- EDN 53.91
- COGT 31.99
- Support Level
- EDN $43.60
- COGT $7.30
- Resistance Level
- EDN $51.69
- COGT $8.56
- Average True Range (ATR)
- EDN 3.21
- COGT 0.67
- MACD
- EDN -0.83
- COGT -0.08
- Stochastic Oscillator
- EDN 22.73
- COGT 16.77
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.